Design, Synthesis and Anti-Alzheimer’s Activity of Some Hybrid Molecule of Oxymatrine Through TGF-β
Current Topics in Medicinal Chemistry · 2026
DOI: 10.2174/0115680266345212250404071300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Topics in Medicinal Chemistry, 2026. Verfasst von Subhendu Ghosh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur Chhattisgarh, 495009, India. Hauptthemen laut MEDLINE: Alkaloids, Quinolizines, Alzheimer Disease, Transforming Growth Factor beta. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Aims
This study aimed to investigate novel therapeutic approaches for Alzheimer's disease (AD) by targeting the Transforming Growth Factor-β (TGF-β) pathway using hybrid compounds derived from oxymatrine and amino acids.
Background
AD remains a significant challenge in neurodegenerative disorders, necessitating innovative treatments that can mitigate its devastating effects. The TGF-β pathway has been implicated in AD pathogenesis, making it a promising target for therapeutic intervention.
Objective
The objective of this study was to synthesize and evaluate the anti-AD activity of hybrid molecules combining oxymatrine with different amino acids. These compounds were designed to enhance blood-brain barrier permeability and selectively modulate TGF-β signaling.
Methods
Hybrid compounds were synthesized based on molecular docking studies. Characterization of synthesized compounds was performed using thin-layer chromatography (TLC), infrared spectroscopy (IR), and nuclear magnetic resonance (NMR) spectroscopy. Anti-AD activity was assessed using an AD rat model induced by a high-cholesterol diet, employing behavioral tests (radial arm maze and Hebb’s Williams maze) and biochemical assays to measure Aβ and TGF-β levels.
Results
All hybrid molecules exhibited significant anti-AD activity, with compound 3B demonstrating the highest efficacy at a dose of 100 mg/kg. Biochemical analyses revealed modulation of Aβ and TGF-β levels, indicating the compounds' potential therapeutic effects against AD.
Conclusion
This study unveils a new class of hybrid compounds derived from oxymatrine and amino acids that effectively target the TGF-β pathway, offering promising therapeutic potential for AD. These compounds demonstrate neuroprotective properties, suggesting they may mitigate ADrelated pathology, including tau deposition, synaptic dysfunction, and cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur Chhattisgarh, 495009, India.
ORCID-Profile: Yogita Dhurandhar
Zitieren
APA
Ghosh, S., Dhurandhar, Y., Sahoo, M. K., Chowdhury, D., Das, A., Verma, D., Bodakhe, S. H., Agnihotri, J., & Namdeo, K. P. (2026). Design, Synthesis and Anti-Alzheimer’s Activity of Some Hybrid Molecule of Oxymatrine Through TGF-β. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/0115680266345212250404071300
Vancouver
Ghosh S, Dhurandhar Y, Sahoo MK, Chowdhury D, Das A, Verma D, et al. Design, Synthesis and Anti-Alzheimer’s Activity of Some Hybrid Molecule of Oxymatrine Through TGF-β. Current Topics in Medicinal Chemistry. 2026. doi:10.2174/0115680266345212250404071300
BibTeX
@article{Ghosh2026,
author = {Ghosh, Subhendu and Dhurandhar, Yogita and Sahoo, Manoj Kumar and Chowdhury, Durlav and Das, Ashmita and Verma, Deepshikha and Bodakhe, Surendra H and Agnihotri, Jaya and Namdeo, Kamta P},
title = {Design, Synthesis and Anti-Alzheimer’s Activity of Some Hybrid Molecule of Oxymatrine Through TGF-β},
journal = {Current Topics in Medicinal Chemistry},
year = {2026},
doi = {10.2174/0115680266345212250404071300}
}
EUVIMED